Her PhD project focusses on crossing barriers with combinational drug therapy in adult and pediatric high-grade glioma. Adult and pediatric patients with high-grade glioma (HGG), such as glioblastoma (GBM) and H3K27M-altered diffuse midline glioma (DMG) suffer from a dismal prognosis and a poor quality of life. Drug therapies have largely failed due to inadequate delivery of effective drugs in vitro to the brain as a result of the blood-brain barrier (BBB) preventing most drugs from entering. Recently, focused ultrasound-mediated blood-brain barrier disruption (FUS-BBBD) has emerged as a promising clinically available technology that allows for better delivery of therapeutics to the brain. This allows for the repurposing and delivery of drugs that are effective in vitro but have been discarded because of limited uptake in the brain. How the right (repurposed) drugs in the optimal combination can be delivered, with the best timing (pharmacokinetics) via FUS-BBBD, has yet to be ascertained. In this preclinical project she and colleagues will work towards optimal clinical translation by preclinically investigating combinational drug regimens delivered via FUS-BBBD in mouse models of GBM/DMG.